HomeNDC LookupIngredientsCiclopirox Olamine › 45802-0400-49
Ciclopirox Olamine 7.7 mg/mL Suspension — NDC 45802-0400-49 package photo

Ciclopirox Olamine 7.7 mg/mL Suspension

by Padagis Israel Pharmaceuticals Ltd · 1 BOTTLE in 1 CARTON (45802-400-49) / 30 mL in 1 BOTTLE
NDC 45802-0400-49
🏷️ FDA NDC (as labeled) 45802-400-49 billing pads the product segment with a zero
This package
Contains30 mL in 1 bottle Cost per mL$0.7500 NADAC Per package$22.50 / 30 ml Pack sizes2 compare ↓
Also priced by: Medicaid pays $0.9783/unit · Part D plans $1.14/unit — full pricing hub ↓
Also comes in: 60 mL 45802-0400-46
Rx only Generic On market Non-controlled
🗂️ Data synced Aug 20, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →

🆔 Identity & classification

FDA NDC (as labeled) 45802-400-49
Product NDC 45802-400
11-digit billing NDC 45802040049
NCPDP billing unit ML — per mL (volume)
RxCUI 309290
UNII 50MD4SB4AP
Application # ANDA077676
SPL Set ID eadbd29d-5990-4987-833f-40cd0b2d2868
Mechanism of action Protein Synthesis Inhibitors
Physiologic effect Decreased DNA Replication; Decreased Protein Synthesis; Decreased RNA Replication
DEA schedule Non-controlled
Marketing category ANDA
Marketing status On market
FDA listing status Listed (active directory)
Marketing start 2006-12-29
Route TOPICAL
Dosage form SUSPENSION
Substance CICLOPIROX OLAMINE
GCN Seq No 040298
GCN 95353
HICL code 003203
Ingredient (HICL) Ciclopirox Olamine
HIC1 code Q
Therapeutic class — broad (HIC1) Ear/Eye/Nose/Rectum/Topical/Vagina/Other
HIC2 code Q5
Therapeutic class — intermediate (HIC2) Agents Acting Principally On The Skin
HIC3 code Q5F
Therapeutic class — specific (HIC3) Topical Antifungals
AHFS code 84:04.08.20
AHFS class Hydroxypyridones (Skin, Mucous Membrane)
FDB label name CICLOPIROX 0.77% TOPICAL SUSP
FDB brand name Ciclopirox
Legend status F — Federal legend — prescription drug or device
TE code (Orange Book) AB · RLD · RS
Why two NDCs? The FDA registers this code as 45802-400-49 — a 5-3-2 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the product segment → 45802-0400-49. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.

🏷️ RxNorm drug class

This medicine belongs to the Other antifungals for topical use class.

Drug family (ATC) Other antifungals for topical use, Other antiinfectives and antiseptics
How it works Protein Synthesis Inhibitors
Where does this data come from?
Therapeutic classes from RxNorm RxClass (U.S. National Library of Medicine) — Established Pharmacologic Class (FDA), ATC drug family (WHO) and mechanism of action, matched by this product’s RxCUI.

🏭 Manufacturer & labeler

LabelerPadagis Israel Pharmaceuticals Ltd
Application holderPADAGIS ISRAEL PHARMACEUTICALS LTD
FDA applicationANDA077676 (ANDA)
Labeler code45802
First marketedDec 2006
Product typeHuman Prescription Drug
Portfolio175 products on file
The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.

🩺 Clinical

Label name CICLOPIROX 0.77% TOPICAL SUSP Ingredient Ciclopirox Olamine
📗 Our plain-language guide HelloPharmacist
  • Fungal nail infections are slow to clear, and Ciclodan nail lacquer is no exception. In clinical studies, treatment lasted up to 48 weeks. Only a small percentage of patients achie...
  • How long does it take for the nail lacquer to work?
  • No — that's actually one of the most important things to get right. You apply Ciclodan once a day and leave it on. Each new coat goes right on top of the previous one. After seven...
  • Do I need to remove the nail lacquer every night before I apply a new coat?
📖 Read our full Ciclopirox Topical guide →
Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.

🧪 Inactive Ingredients / Excipients

Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.

💡 Tap an ingredient (hover on desktop) to see what it is and why it’s used.

  • UNII LKG8494WBH
    Benzyl alcohol is a clear liquid used as a preservative and solvent in medicines. It helps prevent bacterial and fungal growth and dissolves other ingredients to create uniform liquid formulations.
  • UNII 936JST6JCN
    Cetyl alcohol is a waxy, fatty substance derived from plant or animal sources. It acts as an emulsifier and thickener in medicines, helping blend oil and water components and giving products a smooth, creamy texture.
  • UNII 33X04XA5AT
    Lactic acid is a naturally occurring organic acid derived from milk or plant sources. It lowers and maintains pH in formulations, helps preserve the product, and can enhance ingredient stability and absorption.
  • UNII N6K5787QVP
    Light mineral oil is a clear, odorless liquid derived from petroleum. In medicines, it acts as a lubricant and emollient to help the product spread smoothly and improve texture.
  • UNII V42034O9PU
    A fatty alcohol derived from coconut or palm oil. It serves as an emulsifier and thickener to help blend oil and water in creams or lotions, and improves the product's texture and consistency.
  • UNII 461N1O614Y
    A synthetic oily liquid used as an emollient and solvent in medications. It helps dissolve active ingredients and improves how the medicine spreads or absorbs through the skin.
  • UNII CAL22UVI4M
    A synthetic emulsifier derived from sorbitol and fatty acids. It helps mix oil and water-based ingredients together and improves the texture and stability of the medicine.
  • UNII NVZ4I0H58X
    A waxy substance made from sorbitol and stearic acid. It acts as an emulsifier and stabilizer, helping keep oil and water mixed together and preventing separation in the medicine.
  • UNII 2KR89I4H1Y
    Stearyl alcohol is a waxy, fatty substance derived from natural oils or made synthetically. It acts as an emulsifier and thickener in medicines, helping mix ingredients together and give the product the right texture.
  • UNII 059QF0KO0R
    Water is a liquid solvent that dissolves and mixes ingredients together in liquid medicines, syrups, and injections. It helps distribute the active drug evenly throughout the product.

10 inactive ingredients listed in the exact product block matched to this NDC.

Where does this data come from?
Data sourced from official FDA Structured Product Labeling (SPL) via DailyMedingredient classCode="IACT" elements from the exact product block matched by this NDC. Label-section narrative from DailyMed / the openFDA label index is shown separately when available.

Inactive ingredient FAQ

Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.

💲 Pricing

A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.

Price systemPer mLPer package
Retail pharmacies payNADAC · weekly $0.750 $22.50 / 30 ml
Medicaid paysCMS SDUD · 12 mo $0.9783 $29.35 / 30 ml
Medicare drug plans payPart D · Q2 2026 $1.14 $34.06 / 30 ml
NADAC price history (per mL) — tap or hover for the price & month
Nov 2021 Jul 2022 Dec 2025 Aug 2026 $1.224 $0.553
▼ Down 34% over the last 24 months.
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.

🔁 Therapeutic equivalents

ProductLabelerPackNADAC/unitTEStatusPrice vs. this
Ciclopirox Olamine 7.7 mg/mLthis 45802-0400-49 Padagis 1 bottle $0.750 AB Availability likely
Ciclopirox Olamine 7.7 mg/100mL 63629-2522-01 Bryant 1 bottle AB FDA listed
Ciclopirox Olamine 7.7 mg/100mL 63629-8627-01 Bryant 1 bottle AB FDA listed
Ciclopirox Olamine 7.7 mg/100mL 71335-2717-01 Bryant 1 bottle AB FDA listed
Ciclopirox Olamine 7.7 mg/100mL 71335-2915-01 Bryant 1 bottle AB FDA listed
Ciclopirox Olamine 7.7 mg/100mL 72162-1406-03 Bryant 1 bottle AB FDA listed
About this product: this is a generic version of the medicine. FDA equivalence ratings are shown when available, and other versions are listed above, least expensive first.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.

Availability & generic status

🏛️
2006
On the market since
Dec 2006
📍
2026
Currently FDA-listed
20 years listed
🔓
·
Generic on the market
this product is a generic
This is a generic drug

This product is an FDA-approved generic. Other versions of the same drug are listed under Therapeutic equivalents, least expensive first.

Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.

🗺️ Medicaid utilization & spend

📍 This exact package only: Medicaid data is reported per full 11-digit NDC — labeler, product and pack size — so every number here is for 45802-0400-49, not the drug overall. Other pack sizes report separately.
💊 Pharmacy benefit only: These are Medicaid outpatient pharmacy claims, billed by NDC. They exclude the medical benefit — clinic- or hospital-administered drugs billed under HCPCS J-codes — so drugs used mostly that way (e.g. Avastin, Lucentis, Keytruda) can look low or missing here. That’s expected, not an error.
📅 Q1 2025 – Q4 2025 · 4 quarters of data
ⓘ The newest quarter is usually incomplete when first published; states restate recent quarters in later CMS releases, so the latest figures typically revise upward. State coverage-policy changes can also shift quarter-to-quarter totals.
Prescriptions last 4 qtrs
3.9K
Units reimbursed last 4 qtrs
137.2K
Gross reimbursed last 4 qtrs
$134.2K
Avg / prescription
$34.62
Avg / unit
$0.9783
Latest quarter Q4 2025
907Rx
Medicaid pays / mL
$0.9783
gross reimbursed
vs
NADAC / mL
$0.7500
acquisition cost
=
Spread
+$0.2283
+30% vs cost
What Medicaid paid per mL (before rebates; includes the pharmacy’s dispensing fee) compared with NADAC — the average price pharmacies pay to buy the drug. A positive spread means Medicaid reimbursed more than the purchase price, before manufacturer rebates.
Fee-for-service vs managed care
57% FFS 43% MCO
Fee-for-service · 2,205 Rx Managed care · 1,671 Rx
State Medicaid map
Alaska: no data reported AK Maine: no data reported ME Washington: 3,960 units · 50.7 per 100k residents WA Idaho: no data reported ID Montana: no data reported MT North Dakota: no data reported ND Minnesota: no data reported MN Wisconsin: no data reported WI Michigan: no data reported MI New York: 66,015 units · 337 per 100k residents NY Vermont: no data reported VT New Hampshire: no data reported NH Oregon: no data reported OR Nevada: no data reported NV Wyoming: no data reported WY South Dakota: no data reported SD Iowa: no data reported IA Illinois: no data reported IL Indiana: no data reported IN Ohio: 6,018 units · 51.1 per 100k residents OH Pennsylvania: no data reported PA New Jersey: 31,763 units · 342 per 100k residents NJ Massachusetts: no data reported MA California: 5,623 units · 14.4 per 100k residents CA Utah: no data reported UT Colorado: no data reported CO Nebraska: no data reported NE Missouri: 7,837 units · 126 per 100k residents MO Kentucky: no data reported KY West Virginia: no data reported WV Virginia: no data reported VA Maryland: 1,110 units · 18.0 per 100k residents MD Connecticut: no data reported CT Rhode Island: no data reported RI Arizona: no data reported AZ New Mexico: no data reported NM Kansas: no data reported KS Arkansas: no data reported AR Tennessee: no data reported TN North Carolina: no data reported NC South Carolina: no data reported SC Delaware: no data reported DE Oklahoma: no data reported OK Louisiana: no data reported LA Mississippi: 6,900 units · 235 per 100k residents MS Alabama: no data reported AL Georgia: 420 units · 3.8 per 100k residents GA D.C.: no data reported DC Hawaii: no data reported HI Texas: 748 units · 2.5 per 100k residents TX Florida: 6,765 units · 29.9 per 100k residents FL
Units reimbursed · per 100k residents
2.5342
gray = no data reported
Colors are per 100,000 residents, so big states don’t automatically dominate. Tap or hover a state for its actual totals.
Tap or hover a state
…for its Medicaid breakdown
🏆 Top states by units · per 100k residents
1 New Jersey 342 /100k
2 New York 337 /100k
3 Mississippi 235 /100k
4 Missouri 126 /100k
5 Ohio 51.1 /100k
6 Washington 50.7 /100k
7 Florida 29.9 /100k
8 Maryland 18.0 /100k
National units — by quarter
💵 About the dollar figures: “reimbursed” is what Medicaid paid pharmacies before confidential manufacturer rebates, so the program’s real net cost is lower than these numbers. Fee-for-service and managed-care claims are combined unless split above. Source: CMS State Drug Utilization Data; per-100k rates use 2023 Census population estimates.

💊 Medicaid utilization by pack size

Medicaid (SDUD) totals over the four most recent reported quarters for every package size of this drug — handy when a specific package (e.g. a starter/titration pack) carries little or no Medicaid volume on its own.
1 bottle45802-0400-46 8,193 Rx · $591,901
1 bottle this page45802-0400-49 3,876 Rx · $134,178
Drug total (last 4 qtrs): 12,069 Rx · 616,732 units · $726,079 gross reimbursed
Tap a pack size to open its page. Source: CMS State Drug Utilization Data, last 4 quarters.

📊 Medicare Part D spend CMS · PART D · 2026 (Q1)

Medicare Part D (outpatient prescription) spending for Ciclopirox (matched by generic name) — the program that covers self-administered drugs. 6 manufacturers.
⚠️ Drug-level data: CMS publishes Part D spending by drug, not by NDC — these figures combine every manufacturer, strength and package size sold under the name Ciclopirox. That’s a different level of aggregation than the Medicaid card above, which is specific to this exact 11-digit NDC (pack size included), so the two aren’t directly comparable.
Period
Total Part D spend
$3.34M
Claims incl. refills
125.3K
Beneficiaries
93.6K
Spend / beneficiary
$35.64
Spend / claim
$26.62
Trend by period
💵 About the dollar figures: spending is what Part D plans paid before confidential manufacturer rebates, so the program’s real net cost is lower. A blank patient count means fewer than 11 people — CMS hides counts that small to protect privacy. Source: CMS Medicare Quarterly Part D Spending by Drug (data.cms.gov), updated quarterly.

🔬 Reported adverse events (FAERS)

Read carefully: FAERS reports are voluntary and unverified. Counts are not incidence, do not establish causation, are subject to reporting bias, and cannot be used to compare one drug to another. Shown for signal context only. Reports for CICLOPIROX OLAMINE — the ingredient across all brands.

Top reported reactions

Device Dislocation78
Device Malfunction78
Rash25
Fatigue22
Pruritus21
Condition Aggravated17
Pain17

Age at onset

Adult50
Elderly25

Reporter sex

470 reports
Male · 61%
Female · 39%
Unknown · 1%

Serious outcomes

Hospitalization200
Life-threatening37
Disabling26
Death15
Reports over time (by year) — tap or hover for the count & year
2019 2021 2023 2026 63 14
Most recent year is provisional (FAERS lags ~3 months).
Where does this data come from?
Adverse-event reports from the FDA Adverse Event Reporting System (FAERS) via openFDA. FAERS reports are voluntary and unverified — counts are not incidence and don’t establish causation.

📦 Packaging — all sizes for this product

Package NDCDescription Per unit Per pack Marketing startStatus
45802-0400-46 1 BOTTLE in 1 CARTON (45802-400-46) / 60 mL in 1 BOTTLE $0.7331 / mL $43.98 2006-12-29 Active
45802-0400-49 You're viewing this 1 BOTTLE in 1 CARTON (45802-400-49) / 30 mL in 1 BOTTLE $0.7500 / mL $22.50 2006-12-29 Active

This pack accounts for about 32% of this product's recent Medicaid fills; most go to a different pack size. See all packs ↓

Pack size FAQ

What quantity is in NDC 45802-0400-49?
NDC 45802-0400-49 is listed by the FDA — 1 bottle in 1 carton / 30 ml in 1 bottle.
What NDC number is used to bill for this package of Ciclopirox Olamine 7.7 mg/mL Suspension?
Bill NDC 45802-0400-49 — the 11-digit billing format is 45802040049. Pharmacy and medical claims use the 11-digit form; the FDA label may print a shorter form of the same code.

Prices are the latest CMS NADAC pharmacy acquisition cost per NDC; per-pack figures are per-unit × pack quantity, shown only when the pack is denominated in the same measure NADAC prices.

📄 Full prescribing information FDA SPL

The complete FDA label for this product — the official prescribing information, verbatim, section by section. Jump with a chip, search within the label, or expand everything.
🎯 Indications and Usage 54 words

INDICATIONS AND USAGE Ciclopirox Olamine Topical Suspension USP, 1.0% is indicated for the topical treatment of the following dermal infections: tinea pedis, tinea cruris and tinea corporis due to Trichophyton rubrum, Trichophyton mentagrophytes, Epidermophyton floccosum, and Microsporum canis; cutaneous candidiasis (moniliasis) due to Candida albicans; and tinea (pityriasis) versicolor due to Malassezia furfur .

⏱️ Dosage and Administration 81 words

DOSAGE AND ADMINISTRATION Gently massage Ciclopirox Olamine Topical Suspension USP, 1.0% into the affected and surrounding skin areas twice daily, in the morning and evening. Clinical improvement with relief of pruritus and other symptoms usually occurs within the first week of treatment. If a patient shows no clinical improvement after four weeks of treatment with Ciclopirox Olamine Topical Suspension USP, 1.0% the diagnosis should be redetermined.

Patients with tinea versicolor usually exhibit clinical and mycological clearing after two weeks of treatment.

Contraindications 20 words

CONTRAINDICATIONS Ciclopirox Olamine Topical Suspension USP, 1.0% is contraindicated in individuals who have shown hypersensitivity to any of its components.

⚠️ Warnings 20 words

WARNINGS General - Ciclopirox Olamine Topical Suspension USP, 1.0% is not for ophthalmic use. Keep out of reach of children.

🤒 Adverse Reactions 88 words

ADVERSE REACTIONS In the controlled clinical trial with 89 patients using ciclopirox olamine topical suspension and 89 patients using the vehicle, the incidence of adverse reactions was low. Those considered possibly related to treatment or occurring in more than one patient were pruritus, which occurred in two patients using ciclopirox olamine topical suspension and one patient using the suspension vehicle, and burning, which occurred in one patient using ciclopirox olamine topical suspension. To report SUSPECTED ADVERSE REACTIONS, contact Padagis ® at 1-866-634-9120 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

🤰 Pregnancy 175 words

Pregnancy Teratogenic Effects There are no adequate or well-controlled studies in pregnant women. Therefore, Ciclopirox Olamine Topical Suspension USP, 1.0% should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Oral embryofetal developmental studies were conducted in mice, rats, rabbits and monkeys.

Ciclopirox or ciclopirox olamine was orally administered during the period of organogenesis. No maternal toxicity, embryotoxicity or teratogenicity were noted at the highest doses of 77, 125, 80 and 38.5 mg/kg/day ciclopirox in mice, rats, rabbits and monkeys, respectively (approximately 11, 37, 51 and 24 times the maximum recommended human dose based on body surface area comparisons, respectively). Dermal embryofetal developmental studies were conducted in rats and rabbits with ciclopirox olamine dissolved in PEG 400.

Ciclopirox olamine was topically administered during the period of organogenesis. No maternal toxicity, embryotoxicity or teratogenicity were noted at the highest doses of 92 mg/kg/day and 77 mg/kg/day ciclopirox in rats and rabbits, respectively (approximately 27 and 49 times the maximum recommended human dose based on body surface area comparisons, respectively).

🧒 Pediatric Use 19 words

Pediatric Use - Safety and effectiveness in pediatric patients below the age of 10 years have not been established.

🧬 Clinical Pharmacology 206 words

CLINICAL PHARMACOLOGY Mechanism of Action Ciclopirox is a hydroxypyridone antifungal agent that acts by chelation of polyvalent cations (Fe 3+ or Al 3+ ), resulting in the inhibition of the metal-dependent enzymes that are responsible for the degradation of peroxides within the fungal cell. Pharmacokinetics Pharmacokinetic studies in men with radiolabeled ciclopirox solution in polyethylene glycol 400 showed an average of 1.3% absorption of the dose when it was applied topically to 750 cm 2 on the back followed by occlusion for 6 hours.

The biological half-life was 1.7 hours and excretion occurred via the kidney. Two days after application only 0.01% of the dose applied could be found in the urine. Fecal excretion was negligible.

Autoradiographic studies with human cadaver skin showed that ciclopirox penetrates into the hair and through the epidermis and hair follicles into the sebaceous glands and dermis, while a portion of the drug remains in the stratum corneum. In vitro penetration studies in frozen or fresh excised human cadaver and pig skin indicated that the penetration of ciclopirox olamine topical suspension, 1.0% is equivalent to that of ciclopirox olamine cream 1.0%. Therapeutic equivalence of cream and suspension formulations was also indicated by studies of experimentally induced guinea pig and human trichophytosis.

📦 How Supplied / Storage and Handling 37 words

HOW SUPPLIED Ciclopirox Olamine Topical Suspension USP, 1.0% is available as follows: 30 mL bottle (NDC 45802- 400 -49) 60 mL bottle (NDC 45802- 400 -46) Bottle space provided to allow for vigorous shaking before each use.

📦 Storage and Handling 15 words

Store at 20° to 25° C (68° to 77° F) [see USP Controlled Room Temperature].

📋 Description 119 words

DESCRIPTION Ciclopirox Olamine Topical Suspension USP, 1.0% is for topical use. Each gram of Ciclopirox Olamine Topical Suspension USP, 1.0% contains 10 mg of ciclopirox olamine equivalent to 7.70 mg of ciclopirox in a water miscible suspension base consisting of benzyl alcohol NF, cetyl alcohol NF, lactic acid USP, light mineral oil NF, myristyl alcohol NF, octyldodecanol NF, polysorbate 60 NF, purified water USP, sorbitan monostearate NF, and stearyl alcohol NF. Ciclopirox Olamine Topical Suspension USP, 1.0% contains a synthetic, broad-spectrum, antifungal agent ciclopirox (as ciclopirox olamine).

The chemical name is 6-cyclohexyl-1-hydroxy-4-methyl-2(1 H )-pyridone, 2-aminoethanol salt. The CAS Registry Number is 41621-49-2. Ciclopirox Olamine Topical Suspension USP, 1.0% has a pH of 7.

The chemical structure is: Structural Formula

💬 Information for Patients 70 words

Information for Patients - The patient should be told to: 1. Use the medication for the full treatment time even though signs/symptoms may have improved and notify the physician if there is no improvement after four weeks. 2. Inform the physician if the area of application shows signs of increased irritation (redness, itching, burning, blistering, swelling, oozing) indicative of possible sensitization. 3. Avoid the use of occlusive wrappings or dressings.

Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA. Prefer the government’s original formatting? View this label on DailyMed ↗
For educational and professional reference only — not medical advice. Pricing reflects published NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.